TTP-399: What Early Studies Show About a New Tool for Type 1 Lows

TTP-399, also known as cadisegliatin, is an oral medication—a pill—that researchers are studying as an add-on therapy for Type 1 diabetes. Unlike insulin, which replaces the hormone your pancreas no longer makes, TTP-399 works in your liver to help prevent your blood sugar from dropping too low.

The medication is still investigational, meaning it hasn't been approved by regulatory agencies yet and is only available through clinical trials. It's designed to work alongside, not instead of, insulin therapy.

In the SimpliciT1 Phase 2 trial, published in Diabetes Care in 2021, participants took 800 mg of TTP-399 daily for 12 weeks. Compared to those who received placebo, people taking TTP-399 had fewer hypoglycemic (low blood sugar) events—approximately half as many. The medication also showed improvements in HbA1c levels and time-in-range.

These early results were promising enough to move forward with larger testing. The CATT1 Phase 3 trial, which is much larger and more rigorous, enrolled 166 participants and completed recruitment in October 2026. Researchers expect to share the results by mid-2027.

While the early data is encouraging, TTP-399 is still being studied. The full picture of its safety and effectiveness won't be clear until the Phase 3 results are analyzed and reviewed by regulators. That means we don't yet know how well it works for different groups of people, what side effects might occur over longer time periods, or how it might interact with other medications or conditions.

Phase 3 trials are specifically designed to answer these important questions before any medication can be considered for approval.

TTP-399 is not a cure for Type 1 diabetes. It does not restore insulin production or change the underlying autoimmune condition. It's also not a replacement for insulin—people taking TTP-399 in the trials continued to use insulin as their primary treatment.

Think of it as a potential safety tool: something that might help reduce the frequency of severe lows when used alongside standard diabetes management.

If you're interested in learning more about TTP-399 clinical trials or think you might be eligible to participate, start a conversation with your healthcare team. They can help you understand whether a trial might be right for you and how to connect with researchers in your area.

In the meantime, stay tuned for Phase 3 results expected in 2027. Until then, TTP-399 remains investigational and educational information only—not a treatment option outside of clinical trials.

Origin: Diet Cultures (Video report). Evidence: Video report — unverified, pending corroboration. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.